Because right now, most medspas are, * Launching GLP-1 offers without tightening intake + documentation * Assuming compounding is a free-for-all forever * Marketing outcomes harder than they manage safety * Getting lots of leads and losing most to slow follow-up The truth is, GLP-1 demand is real, but the tolerance for sloppy programs is shrinking
Using SYMLIN and insulin with type 1 diabetes: When starting SYMLIN, you will need to reduce your dose of mealtime insulin
As one of the largest telehealth providers in the country, it has established relationships with multiple compounding pharmacies, which can mean more consistent supply
doi: 10.1097/md.0000000000034978 107 BendottiGMontefuscoLLunatiMEUsuelliVPastoreILazzaroniEet al
Before treatment, she experienced multi-week flares that significantly impacted quality of life
Wegovy can be injected into the abdomen, thigh, or upper arm